Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 22 peer-reviewed journal articles Updated
Pulmonology · Mycobacterium avium complex pulmonary disease

Is MAC After Culture Conversion a Relapse or Reinfection?

At a Glance

A new positive MAC culture after cultures became negative can mean either the original infection has returned or a different environmental strain has been acquired. Doctors confirm recurrence with repeat sputum samples, symptoms, CT findings, antibiotic testing, and sometimes genetic comparison.

Getting a new positive culture after finishing a grueling treatment is frightening, but a single positive result does not automatically mean your previous treatment failed [1]. Do not start, stop, or change any antibiotics on your own; contact your pulmonary or infectious disease team to determine your next steps.

(If you experience severe new breathlessness, chest pain, coughing up significant amounts of blood, or rapidly worsening illness, seek urgent medical care.)

If your sputum cultures become positive again after achieving culture conversion (which generally means having at least two or three consecutive negative cultures [2][3]), it could be either a relapse or a reinfection:

  • Relapse: The original strain (specific genetic type) of Mycobacterium avium complex (MAC) survived and is growing again [4].
  • Reinfection: You acquired a new strain of MAC from the environment [4].

Having a condition like bronchiectasis (widened, scarred airways that often exist before or alongside MAC) makes you more susceptible to picking up new strains from the environment [5]. In fact, studies of patients with nodular-bronchiectatic MAC disease show that among those who develop a recurrent infection of the same species, 74% to 86% actually have a reinfection with a new strain, rather than a relapse of the old one [6][7].

How Doctors Investigate a New Positive Culture

You cannot reliably tell a relapse from a reinfection just by looking at how much time has passed since your last treatment or by your symptoms alone [4]. Your care team will likely recommend the following steps:

1. Confirm the Recurrence
A single positive sputum culture does not confirm that MAC disease has returned; it could simply be transient presence or sample contamination [8]. Diagnosis typically requires at least two positive sputum cultures (or one from a bronchoscopy), combined with a review of your symptoms and changes on a chest CT scan [2][9].

2. Strain Comparison (Genotyping)
The best available evidence to distinguish relapse from reinfection is genotyping (such as whole-genome sequencing), which compares the genetic fingerprint of the new bacteria to your original saved sample [4][10]. However, this is not always possible if the lab did not save your original isolate (the cultured bacteria) or lacks the technology [10][11].

3. Susceptibility Testing
Your doctor will test the new MAC isolate to see if it is resistant to key antibiotics, especially macrolides (the core MAC drugs, like azithromycin or clarithromycin) and amikacin [12][13]. This is crucial, as macrolide-resistant MAC requires specialized management and redesigned regimens [14].

4. Evaluate Co-infections and Other Factors
Your team will review your past treatment history, check for other infections (like Nocardia) that might explain worsening symptoms [15], and evaluate other host factors [5].

How This Affects Your Next Steps

Distinguishing between relapse and reinfection helps guide your treatment plan. Because reinfection is so common, a new episode does not automatically mean your previous antibiotic regimen was inadequate [1][16].

  • Treatment Options: If the bacteria remain susceptible to macrolides, and depending on your disease severity, MAC species, and imaging, a standard multidrug regimen might still be an option [16]. If the new bacteria show macrolide resistance, a specialist will need to redesign your regimen [13]. Note: Refractory disease (when a current, guideline-based treatment fails to clear the infection after 6 months) is a different situation that may require adding specialized therapies like inhaled liposomal amikacin, which has specific risks and monitoring needs [17][18].
  • Airway Clearance: Continue your individualized airway clearance plan as prescribed. While it cannot guarantee prevention of MAC recurrence, clearing mucus helps manage bronchiectasis and supports overall lung health [19][20].
  • Environmental Precautions: MAC is widespread in water and soil. While you cannot completely eliminate exposure, you can discuss sensible precautions with your doctor—like using a well-fitting mask and gloves when gardening, or avoiding hot-tub aerosols—to reduce your risk without unnecessary fear [21][22].

Common questions in this guide

Does one positive MAC culture prove that the infection is back?
No. A single positive sputum culture can reflect temporary presence or contamination, so it usually does not establish recurrent MAC lung disease. Clinicians generally look for at least two positive sputum cultures, or one positive sample collected during bronchoscopy, together with symptoms and compatible changes on a chest CT scan.
How do doctors distinguish a MAC relapse from a reinfection?
A relapse means the original MAC strain survived and began growing again, while a reinfection means a different strain was acquired from the environment. Genotyping compares the genetic fingerprint of the new bacteria with the original cultured sample when that sample was saved. The comparison may not be possible if the original sample is unavailable or the laboratory lacks the needed technology.
Why can MAC return even after treatment made my cultures negative?
Bronchiectasis can make the airways more vulnerable to acquiring new MAC strains from the environment. MAC is widespread in water and soil, so a later positive culture may be a new infection rather than proof that the previous treatment failed.
What tests are used after another positive MAC culture?
The care team may request additional sputum samples, review symptoms, and compare chest CT scans with earlier images. The new isolate is usually tested to see whether key antibiotics, especially macrolides and amikacin, are likely to work. Doctors may also use genetic comparison when the original isolate is available and evaluate other infections that could explain worsening symptoms.
Will I need to restart MAC antibiotics after a new positive result?
Not necessarily. Treatment depends on whether recurrent disease is confirmed, your symptoms and CT findings, the MAC species, disease severity, and antibiotic susceptibility results. Macrolide-susceptible disease may be treated with a standard multidrug regimen, while macrolide resistance requires specialist-directed changes; do not start, stop, or alter antibiotics without your care team.
What can I do while my doctors evaluate the new culture?
Continue your prescribed airway-clearance plan and discuss practical environmental precautions, such as wearing a well-fitting mask and gloves while gardening and avoiding hot-tub aerosols. Contact your pulmonary or infectious disease team for guidance, and seek urgent care for severe new breathlessness, chest pain, significant coughing up of blood, or rapidly worsening illness.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Was my previous MAC isolate saved by the laboratory, and can we genetically compare it to this new positive culture?
  2. 2.Has this new MAC isolate been tested for macrolide and amikacin susceptibility?
  3. 3.Do I need to submit more sputum samples to confirm if this is true MAC disease recurrence?
  4. 4.How do my current CT scan and symptoms affect the decision to start treatment versus monitoring?
  5. 5.Should I be evaluated by an NTM-specialized pulmonologist or infectious disease expert before starting a new regimen?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

Related questions

Can Pulmonary MAC Cause Lasting Lung Damage or Shorten Life?Can Gardening Expose You to Mycobacterium avium Complex?Can You Have Pulmonary MAC With a Negative AFB Smear?Does an AFB-Positive Sputum Test Mean I Have Tuberculosis?Does a Positive MAC Sputum Culture Always Mean Lung Disease?How Do Doctors Tell if Pulmonary MAC Treatment Is Working?Why Isn't Pulmonary MAC Contagious to Your Family?How Often Are CT Scans and Breathing Tests Used for MAC?How Quickly Does Untreated Pulmonary MAC Disease Progress?How Should I Collect Sputum for Pulmonary MAC Diagnosis?Should I Get Immune or Lung Testing for Pulmonary MAC?What Do CT Scan Findings Mean in Pulmonary MAC Disease?What Factors Affect Your Chances of Clearing Pulmonary MAC?What Follow-Up Is Needed After Pulmonary MAC Treatment?What Tests Check for Disseminated MAC Outside the Lungs?What Tests Diagnose Pulmonary MAC If I Can't Produce Sputum?What Water Precautions Are Recommended for MAC Lung Disease?When Is Watchful Waiting Appropriate for Pulmonary MAC?Why Do MAC Species ID and Macrolide Testing Matter?

References

References (22)
  1. 1

    Microbiologic Outcome of Interventions Against Mycobacterium avium Complex Pulmonary Disease: A Systematic Review.

    Diel R, Nienhaus A, Ringshausen FC, et al.

    Chest 2018; (153(4)):888-921 doi:10.1016/j.chest.2018.01.024.

    PMID: 29410162
  2. 2

    Mycobacterium avium Complex: Addressing Gaps in Diagnosis and Management.

    Daley CL, Winthrop KL

    The Journal of infectious diseases 2020; (222(Suppl 4)):S199-S211 doi:10.1093/infdis/jiaa354.

    PMID: 32814943
  3. 3

    Clinical characteristics and early outcomes of patients newly diagnosed with pulmonary Mycobacterium avium complex disease.

    Hagiwara E, Katano T, Isomoto K, et al.

    Respiratory investigation 2019; (57(1)):54-59 doi:10.1016/j.resinv.2018.08.006.

    PMID: 30366835
  4. 4

    Relapse versus Reinfection of Mycobacterium avium Complex Pulmonary Disease. Patient Characteristics and Macrolide Susceptibility.

    Boyle DP, Zembower TR, Qi C

    Annals of the American Thoracic Society 2016; (13(11)):1956-1961 doi:10.1513/AnnalsATS.201605-344BC.

    PMID: 27599038
  5. 5

    Growing from common ground: nontuberculous mycobacteria and bronchiectasis.

    Van Braeckel E, Bosteels C

    European respiratory review : an official journal of the European Respiratory Society 2024; (33(173)) doi:10.1183/16000617.0058-2024.

    PMID: 38960614
  6. 6

    Outcomes of Mycobacterium avium complex lung disease based on clinical phenotype.

    Koh WJ, Moon SM, Kim SY, et al.

    The European respiratory journal 2017; (50(3)) doi:10.1183/13993003.02503-2016.

    PMID: 28954780
  7. 7

    Intermittent Antibiotic Therapy for Recurrent Nodular Bronchiectatic Mycobacterium avium Complex Lung Disease.

    Jhun BW, Moon SM, Kim SY, et al.

    Antimicrobial agents and chemotherapy 2018; (62(2)) doi:10.1128/AAC.01812-17.

    PMID: 29203483
  8. 8

    Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline.

    Daley CL, Iaccarino JM, Lange C, et al.

    The European respiratory journal 2020; (56(1)) doi:10.1183/13993003.00535-2020.

    PMID: 32636299
  9. 9

    Diagnostic Criteria and the Decision to Treat Nontuberculous Mycobacterial Pulmonary Disease.

    Griffith DE, Aksamit TR

    Clinics in chest medicine 2023; (44(4)):757-769 doi:10.1016/j.ccm.2023.07.003.

    PMID: 37890914
  10. 10

    Understanding recurrence in Mycobacterium avium complex pulmonary disease: genotypic strategies to support clinical decision-making.

    Trinh MP, Shin SJ, Shin M-K

    Journal of clinical microbiology 2026; (64(3)):e0108625 doi:10.1128/jcm.01086-25.

    PMID: 41190925
  11. 11

    Mycobacterium avium Complex-Related Pulmonary Parenchyma Destruction: A Case Report.

    Viswanath A, Manimaran A, Brown J, Solano J

    Cureus 2025; (17(4)):e82097 doi:10.7759/cureus.82097.

    PMID: 40352038
  12. 12

    Variability of Mycobacterium avium Complex Isolates Drug Susceptibility Testing by Broth Microdilution.

    Zimenkov D

    Antibiotics (Basel, Switzerland) 2022; (11(12)) doi:10.3390/antibiotics11121756.

    PMID: 36551413
  13. 13

    Clinical Characteristics, Treatment Outcomes, and Resistance Mutations Associated with Macrolide-Resistant Mycobacterium avium Complex Lung Disease.

    Moon SM, Park HY, Kim SY, et al.

    Antimicrobial agents and chemotherapy 2016; (60(11)):6758-6765 doi:10.1128/AAC.01240-16.

    PMID: 27572413
  14. 14

    Macrolide-Resistant Mycobacterium avium Complex Lung Disease: Analysis of 102 Consecutive Cases.

    Morimoto K, Namkoong H, Hasegawa N, et al.

    Annals of the American Thoracic Society 2016; (13(11)):1904-1911 doi:10.1513/AnnalsATS.201604-246OC.

    PMID: 27513168
  15. 15

    Co-infection with Nocardia spp. in a patient with Mycobacterium avium complex pulmonary disease: A case report.

    Tokita N, Urabe N, Sakamoto S, et al.

    Respirology case reports 2022; (10(10)):e01036 doi:10.1002/rcr2.1036.

    PMID: 36090022
  16. 16

    Mycobacterium avium Complex Disease.

    Daley CL

    Microbiology spectrum 2017; (5(2)) doi:10.1128/microbiolspec.TNMI7-0045-2017.

    PMID: 28429679
  17. 17

    Amikacin Liposome Inhalation Suspension for Treatment-Refractory Lung Disease Caused by Mycobacterium avium Complex (CONVERT). A Prospective, Open-Label, Randomized Study.

    Griffith DE, Eagle G, Thomson R, et al.

    American journal of respiratory and critical care medicine 2018; (198(12)):1559-1569 doi:10.1164/rccm.201807-1318OC.

    PMID: 30216086
  18. 18

    Amikacin Liposome Inhalation Suspension: A Review in Mycobacterium avium Complex Lung Disease.

    Shirley M

    Drugs 2019; (79(5)):555-562 doi:10.1007/s40265-019-01095-z.

    PMID: 30877642
  19. 19

    Investigation and Management of Bronchiectasis in Nontuberculous Mycobacterial Pulmonary Disease.

    McShane PJ

    Clinics in chest medicine 2023; (44(4)):731-742 doi:10.1016/j.ccm.2023.07.005.

    PMID: 37890912
  20. 20

    Nonpharmacological treatment for patients with nontuberculous mycobacterial lung disease.

    Lan CC, Lai SR, Chien JY

    Journal of the Formosan Medical Association = Taiwan yi zhi 2020; (119 Suppl 1()):S42-S50 doi:10.1016/j.jfma.2020.05.013.

    PMID: 32499207
  21. 21

    Mycobacterium avium complex pulmonary disease: new epidemiology and management concepts.

    Lande L, George J, Plush T

    Current opinion in infectious diseases 2018; (31(2)):199-207 doi:10.1097/QCO.0000000000000437.

    PMID: 29346118
  22. 22

    Nontuberculous Mycobacteria Lung Disease (NTM-LD): Current Recommendations on Diagnosis, Treatment, and Patient Management.

    Pathak K, Hart S, Lande L

    International journal of general medicine 2022; (15()):7619-7629 doi:10.2147/IJGM.S272690.

    PMID: 36213301

This page is for informational purposes only and does not constitute medical advice. Your pulmonary or infectious disease team should interpret a new positive MAC culture and guide treatment.

Get notified when new evidence is published on Mycobacterium avium complex disease.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.